Strongbridge Biopharma Stock Price, News & Analysis (NASDAQ:SBBP)

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Strongbridge Biopharma plc (NASDAQ:SBBP) released its earnings results on Wednesday, July, 31st. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.01. The biotechnology company had revenue of $6.08 million for the quarter, compared to analyst estimates of $4.82 million. Strongbridge Biopharma had a net margin of 181.52% and a return on equity of 49.92%. View Strongbridge Biopharma's Earnings History.

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for Strongbridge Biopharma.

Strongbridge Biopharma updated its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $18-20 million, compared to the consensus revenue estimate of $19.49 million.

6 analysts have issued 1 year target prices for Strongbridge Biopharma's shares. Their predictions range from $8.00 to $15.00. On average, they expect Strongbridge Biopharma's stock price to reach $11.50 in the next year. This suggests a possible upside of 477.9% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

News coverage about SBBP stock has been trending somewhat positive recently, according to InfoTrie. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Strongbridge Biopharma earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Strongbridge Biopharma.

Strongbridge Biopharma saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 701,500 shares, an increase of 5.6% from the August 30th total of 664,200 shares. Based on an average daily trading volume, of 164,300 shares, the days-to-cover ratio is presently 4.3 days. Currently, 2.1% of the company's stock are short sold. View Strongbridge Biopharma's Current Options Chain.

Some companies that are related to Strongbridge Biopharma include Progenics Pharmaceuticals (PGNX), Evolus (EOLS), Avedro (AVDR), Crinetics Pharmaceuticals (CRNX), Collegium Pharmaceutical (COLL), Assembly Biosciences (ASMB), Synthorx (THOR), Stemline Therapeutics (STML), Beyondspring (BYSI), AMAG Pharmaceuticals (AMAG), Arcus Biosciences (RCUS), Verrica Pharmaceuticals (VRCA), Magenta Therapeutics (MGTA), DURECT (DRRX) and Merus (MRUS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include Energy Transfer LP Unit (ET), Dicerna Pharmaceuticals (DRNA), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), CBL & Associates Properties (CBL), Dynavax Technologies (DVAX), SunCoke Energy Partners (SXCP), Abeona Therapeutics (ABEO), Ocular Therapeutix (OCUL) and Progenics Pharmaceuticals (PGNX).

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SBBP stock can currently be purchased for approximately $1.99.

Strongbridge Biopharma has a market capitalization of $107.84 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]